The interview series with Algernon Pharmaceuticals CEO Christopher J. Moreau and PRmediaNow host Cyndi Edwards continues. In today’s episode, Mr. Moreau discusses recent news regarding the company’s filing of a pre-IND (Investigational New Drug) meeting request with the U.S. Food and Drug Administration (U.S. FDA) for its investigation of NP-120 (Ifenprodil) for the treatment of small cell lung cancer (SCLC).